MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.

[1]  T. Golub,et al.  MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells , 2016, Science.

[2]  Konstantinos J. Mavrakis,et al.  Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5 , 2016, Science.

[3]  R. DePinho,et al.  Collateral Lethality: A new therapeutic strategy in oncology. , 2015, Trends in cancer.

[4]  Pierre-Jacques Hamard,et al.  Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesis. , 2015, The Journal of clinical investigation.

[5]  Robert A Copeland,et al.  A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. , 2015, Nature chemical biology.

[6]  M. Looso,et al.  Prmt5 is a regulator of muscle stem cell expansion in adult mice , 2015, Nature Communications.

[7]  Alan Ashworth,et al.  Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. , 2015, Annual review of medicine.

[8]  Guido Marcucci,et al.  Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. , 2014, Cancer research.

[9]  Claudio Agostinelli,et al.  Protein Arginine Methyltransferase 5 (PRMT5) Inhibition Induces Lymphoma Cell Death through Reactivation of the Retinoblastoma Tumor Suppressor Pathway and Polycomb Repressor Complex 2 (PRC2) Silencing* , 2013, The Journal of Biological Chemistry.

[10]  Sanjeeb Kumar Sahu,et al.  Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery , 2013, Genes & development.

[11]  Ronan M. T. Fleming,et al.  A community-driven global reconstruction of human metabolism , 2013, Nature Biotechnology.

[12]  Aiping Zhang,et al.  Crystal structure of the human PRMT5:MEP50 complex , 2012, Proceedings of the National Academy of Sciences.

[13]  Zhengxin Wang,et al.  Protein arginine methyltransferase 5 is essential for growth of lung cancer cells. , 2012, The Biochemical journal.

[14]  L. Chin,et al.  Passenger Deletions Generate Therapeutic Vulnerabilities in Cancer , 2012, Nature.

[15]  C. Bountra,et al.  Epigenetic protein families: a new frontier for drug discovery , 2012, Nature Reviews Drug Discovery.

[16]  Hans-Georg Breitinger,et al.  Drug Synergy – Mechanisms and Methods of Analysis , 2012 .

[17]  Ulrike Kutay,et al.  The kinase activity of human Rio1 is required for final steps of cytoplasmic maturation of 40S subunits , 2012, Molecular biology of the cell.

[18]  Zongyang Lv,et al.  Structural insights into protein arginine symmetric dimethylation by PRMT5 , 2011, Proceedings of the National Academy of Sciences.

[19]  A. Kamb,et al.  Methylthioadenosine (MTA) Rescues Methylthioadenosine Phosphorylase (MTAP)-Deficient Tumors from Purine Synthesis Inhibition in Vivo via Non-Autonomous Adenine Supply , 2011 .

[20]  B. Chait,et al.  Protein Arginine Methyltransferase Prmt5-Mep50 Methylates Histones H2A and H4 and the Histone Chaperone Nucleoplasmin in Xenopus laevis Eggs* , 2011, The Journal of Biological Chemistry.

[21]  G. Merlino,et al.  Protein Arginine Methyltransferase 5 Regulates ERK1/2 Signal Transduction Amplitude and Cell Fate Through CRAF , 2011, Science Signaling.

[22]  Gabriela Kalna,et al.  Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase , 2011, Nature.

[23]  K. O. Elliston,et al.  Chemogenetic Analysis of Human Protein Methyltransferases , 2011, Chemical biology & drug design.

[24]  Chang-Hai Tsai,et al.  Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation , 2011, Nature Cell Biology.

[25]  M. Surani,et al.  Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency. , 2010, Genes & development.

[26]  G. Evans,et al.  Growth and Metastases of Human Lung Cancer Are Inhibited in Mouse Xenografts by a Transition State Analogue of 5′-Methylthioadenosine Phosphorylase* , 2010, The Journal of Biological Chemistry.

[27]  A. Sickmann,et al.  RioK1, a New Interactor of Protein Arginine Methyltransferase 5 (PRMT5), Competes with pICln for Binding and Modulates PRMT5 Complex Composition and Substrate Specificity* , 2010, The Journal of Biological Chemistry.

[28]  G. Evans,et al.  Design and synthesis of potent "sulfur-free" transition state analogue inhibitors of 5'-methylthioadenosine nucleosidase and 5'-methylthioadenosine phosphorylase. , 2010, Journal of medicinal chemistry.

[29]  Peter J. Oefner,et al.  Quantification of intermediates of the methionine and polyamine metabolism by liquid chromatography-tandem mass spectrometry in cultured tumor cells and liver biopsies. , 2010, Journal of chromatography. A.

[30]  S. Bao,et al.  Methylation of Ribosomal Protein S10 by Protein-arginine Methyltransferase 5 Regulates Ribosome Biogenesis* , 2010, The Journal of Biological Chemistry.

[31]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[32]  G. V. Van Duyne,et al.  Role of pICLn in Methylation of Sm Proteins by PRMT5 , 2009, The Journal of Biological Chemistry.

[33]  J. D. Benson,et al.  Single-vector inducible lentiviral RNAi system for oncology target validation , 2009, Cell cycle.

[34]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[35]  S. Carr,et al.  A Mitochondrial Protein Compendium Elucidates Complex I Disease Biology , 2008, Cell.

[36]  C. Sardet,et al.  The histone‐binding protein COPR5 is required for nuclear functions of the protein arginine methyltransferase PRMT5 , 2008, EMBO reports.

[37]  Kelly T Williams,et al.  New insights into the regulation of methyl group and homocysteine metabolism. , 2007, The Journal of nutrition.

[38]  A. Roidl,et al.  Yeast Rio1p is the founding member of a novel subfamily of protein serine kinases involved in the control of cell cycle progression , 2002, Molecular microbiology.

[39]  G. Meister,et al.  Methylation of Sm proteins by a complex containing PRMT5 and the putative U snRNP assembly factor pICln , 2001, Current Biology.

[40]  Juri Rappsilber,et al.  The Methylosome, a 20S Complex Containing JBP1 and pICln, Produces Dimethylarginine-Modified Sm Proteins , 2001, Molecular and Cellular Biology.

[41]  S. Pestka,et al.  The Human Homologue of the Yeast Proteins Skb1 and Hsl7p Interacts with Jak Kinases and Contains Protein Methyltransferase Activity* , 1999, The Journal of Biological Chemistry.

[42]  Richard A. Ashmun,et al.  Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.

[43]  D. Vance,et al.  Phosphatidylethanolamine N-methyltransferase from liver. , 1997, Biochimica et biophysica acta.

[44]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[45]  J. Rowley,et al.  Lymphoblastic leukemia with lymphomatous features associated with abnormalities of the short arm of chromosome 9. , 1985, The New England journal of medicine.

[46]  M. Robert-Gero,et al.  Relationship between inhibition of protein methylase I and inhibition of Rous sarcoma virus-induced cell transformation. , 1979, Cancer research.

[47]  J. Bertino,et al.  Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells. , 2004, Oncology research.

[48]  T. Savarese,et al.  Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines. , 1996, Cancer genetics and cytogenetics.

[49]  F. Della Ragione,et al.  Human 5'-deoxy-5'-methylthioadenosine phosphorylase: kinetic studies and catalytic mechanism. , 1988, Advances in experimental medicine and biology.